Publications by authors named "Rachel Laskey"

Claim this Profile
A
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
Michael Szarek, Pierre Amarenco, Alfred Callahan, David DeMicco, Rana Fayyad, Rachel Laskey

J Am Coll Cardiol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
David D Waters, Sripal Bangalore, Rana Fayyad, David A DeMicco, Rachel Laskey

J Clin Lipidol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.
William C Ports, Rana Fayyad, David A DeMicco, Rachel Laskey, Robert Wolk

Clin Drug Investig· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body-Weight Fluctuations and Outcomes in Coronary Disease.
Sripal Bangalore, Rana Fayyad, Rachel Laskey, David A DeMicco, Franz H Messerli

N Engl J Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
Sripal Bangalore, Rana Fayyad, Franz H Messerli, Rachel Laskey, David A DeMicco

Am J Cardiol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
Young Sup Byun, Xiaohong Yang, Weihang Bao, David DeMicco, Rachel Laskey

J Am Coll Cardiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of atorvastatin in Asian patients within clinical trials.
Juliana C N Chan, Alice P S Kong, Weihang Bao, Rana Fayyad, Rachel Laskey

Cardiovasc Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).
Benoit J Arsenault, Payal Kohli, Gilles Lambert, David A DeMicco, Rachel Laskey

Am J Cardiol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
Sripal Bangalore, Rana Fayyad, John J Kastelein, Rachel Laskey, Pierre Amarenco

Am J Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Prakash C Deedwania, Peter H Stone, Rana S Fayyad, Rachel E Laskey, Daniel J Wilson

Drugs Aging· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
Young Sup Byun, Jun-Hee Lee, Benoit J Arsenault, Xiaohong Yang, Weihang Bao, Rachel Laskey

J Am Coll Cardiol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
Robert M Stoekenbroek, S Matthijs Boekholdt, Rana Fayyad, Rachel Laskey, Matti J Tikkanen

Heart· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL.
Payal Kohli, David D Waters, Rita Nemr, Benoit J Arsenault, Michael Messig, Rachel Laskey

J Am Coll Cardiol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
Priscilla Y Hsue, Vera A Bittner, John Betteridge, Rana Fayyad, Rachel Laskey

Am J Cardiol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Sripal Bangalore, Rana Fayyad, Rachel Laskey, David DeMicco, Prakash Deedwania

Eur Heart J· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Sripal Bangalore, Rana Fayyad, G Kees Hovingh, Rachel Laskey, Liffert Vogt

Am J Cardiol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.
Sripal Bangalore, Rana Fayyad, Rachel Laskey, David A Demicco, Prakash Deedwania

Am J Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Matti J Tikkanen, Rana Fayyad, Ole Faergeman, Anders G Olsson, Chuan-Chuan Wun, Rachel Laskey

Int J Cardiol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies.
Kuan Gandelman, Gordon L Fung, Michael Messig, Rachel Laskey

Am J Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.
Kuan Gandelman, Paul Glue, Rachel Laskey, Jonathan Jones, Robert LaBadie

Pediatr Cardiol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.
Murray Epstein, Elizabeth Leary, Rachel Laskey, Andrea Zuckerman, David Reed

J Cardiometab Syndr· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis